Oksana Gurtovaya

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy”.

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

RMD Open(2020)10.1136/rmdopen-2020-001490

N/A

1.5DataRank · unranked

43 citations

Yashaar Chaichian, Mark C. Genovese, Vimal K. Derebail, Panduranga S. Rao, Winn Chatham +7 more

No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib

Leukemia & lymphoma/Leukemia and lymphoma(2020)10.1080/10428194.2020.1845339

N/A

0.200DataRank · unranked

2 citations

Peter Hillmen, Gilles Salles, Jeff P. Sharman, Stephan Stilgenbauer, Oksana Gurtovaya +6 more